Peter van der Velden, a Director, acquired 1,993 Common Shares on an indirect ownership basis for registered holder Lumira Capital IV (International) L.P. and 74,169 Common Shares on an indirect ownership basis for registered holder Lumira Capital IV, L.P. at a price of $2.363 through a prospectus or prospectus exempt offering on March 31st, 2020. This represents a $180,001 investment into the company's shares and an account share holdings change of greater than 100%.
Stephen William Nelson, a Director, acquired 1,269 Common Shares on an indirect ownership basis for registered holder Kathryn Nelson - RRSP, 634 Common Shares on an indirect ownership basis for registered holder RRSP and 952 Common Shares on an indirect ownership basis for registered holder Stephen & Kathryn Nelson - RESP at a price of $2.363 through a prospectus or prospectus exempt offering on March 31st, 2020. This represents a $6,748 investment into the company's shares and an account share holdings change of 2.4%.
Medexus Pharmaceuticals is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc, is a Canada-based company engaged in pharmaceutical business sector. The Company is a North American focused, specialty pharmaceutical business that operates through three segments: Medac Pharma USA, a fully integrated commercial infrastructure focused on auto-immune diseases in the United States; Medexus Pharma Canada, a fully integrated commercial infrastructure focused on auto-immune disease and pediatric diseases in Canada; and a Business Development function, which works to maintain its product pipeline. The Company's flag products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an allergy medication. The Company provides products for the healthcare professionals and patients.
No Comments